Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27217877 | 0.95 | SSTR4 (0.34) | SSTR4PDPK1LCKSRCTEK | |
| SCHEMBL30813372 | 0.82 | LCK (0.35) | SSTR4PDPK1LCKSRCTEK | |
| SCHEMBL30813409 | 0.80 | USP30 (0.39) | PDPK1 | |
| SCHEMBL20692747 | 0.78 | SRC (0.39) | PDPK1SRC | |
| SCHEMBL27217986 | 0.77 | LCK (0.35) | PDPK1LCKSRCTEKKDM4E | |
| SCHEMBL30813359 | 0.76 | FLT3 (0.36) | PDPK1KDM4EALDH1A1LMNAHTT | |
| SCHEMBL27218030 | 0.76 | PDPK1 (0.33) | PDPK1KDM4EALDH1A1LMNAHTT | |
| SCHEMBL30813659 | 0.76 | PDPK1 (0.33) | PDPK1KDM4EALDH1A1LMNAHTT | |
| SCHEMBL27217794 | 0.76 | USP30 (0.37) | LCKSRCTEK | |
| SCHEMBL30813431 | 0.76 | SRC (0.36) | LCKSRCTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | SSTR4 4781/4885PDPK1 730/4885LCK 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.